FYPERIX COMBO 134 MG/120,6 MG SPOT-ON SOLUTION FOR MEDIUM DOGS
FYPERIX COMBO 134 MG/120,6 MG SPOT-ON SOLUTION FOR MEDIUM DOGS
Authorised
- Fipronil
- Methoprene
Product identification
Medicine name:
FYPERIX COMBO 134 MG/120,6 MG SPOT-ON SOLUTION FOR MEDIUM DOGS
Amflee Combo 134 mg/120,6 mg 100 mg/ml Spot-on oplossing
Amflee Combo 134 mg/120,6 mg 100 mg/ml Solution pour spot-on
Amflee Combo 134 mg/120,6 mg 100 mg/ml Lösung zum Auftropfen
Active substance:
- Fipronil
- Methoprene
Target species:
-
Dog
Route of administration:
-
Cutaneous use
Product details
Active substance and strength:
-
Fipronil134.00/milligram(s)1.00Pipette
-
Methoprene120.60/milligram(s)1.00Pipette
Pharmaceutical form:
-
Spot-on solution
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QP53AX65
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Belgium
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
- KRKA tovarna zdravil d.d. Novo mesto
Marketing authorisation date:
Manufacturing sites for batch release:
- TAD Pharma GmbH
- KRKA tovarna zdravil d.d. Novo mesto
Responsible authority:
- Federal Agency For Medicines And Health Products
Authorisation number:
- BE-V498560
Date of authorisation status change:
Reference member state:
-
France
Procedure number:
- FR/V/0333/003
Concerned member states:
-
Austria
-
Belgium
-
Czechia
-
Estonia
-
Germany
-
Greece
-
Italy
-
Netherlands
-
Poland
-
Portugal
-
Romania
-
Spain
-
United Kingdom (Northern Ireland)
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
This document does not exist in this language (English). You can find it
in another language below.
Package Leaflet
This document does not exist in this language (English). You can find it
in another language below.